ReviewFrontiers in neurology2026
What happens in vagus.
Review in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The parasympathetic nervous system is phylogenetically ancient. In humans, the vagus nerve is the brain's only pathway for bidirectional parasympathetic signaling with the thorax, abdomen, and upper pelvis. Unsurprisingly, the vagus nerve has played a significant role in scientific discovery and therapeutic applications, attracting the attention of Galen, Darwin, and Pavlov, among others. For example, Otto Loewi used the vagus nerve to gather data that confirmed Santiago Ramón y Cajal's Neuron Doctrine. This intensive focus has led to a number of clinical advances related to vagus nerve function, including theories about mind-body connections. Interestingly, reducing vagus nerve activity has been a successful strategy for some clinical conditions, such as peptic ulcer disease and obesity. In other conditions, increasing vagus nerve activity has been successful at improving patient outcomes, for example, in refractory seizures, drug-resistant depression, and stroke recovery; in each of these three conditions, the FDA has approved vagus nerve stimulation as a therapeutic intervention. Potential future developments in the therapeutic modulation of vagus nerve activity are discussed, including its role in perinatal brain development; manipulation of the vagus nerve as a portal for CNS access, as suggested in Parkinson's disease; and closed-loop systems that modulate vagus nerve activity in response to measurement of various forms of signaling, an approach that would be aided by the capacity to directly measure activity in individual vagus nerves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.